

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

S. Gillessen, A. Omlin, G. Attard, J. S. de Bono, E. Efstathiou, K. Fizazi, S. Halabi, P. S. Nelson, O. Sartor, M. R. Smith, H. R. Soule, H. Akaza, T. M. Beer, H. Beltran, A. M. Chinnaiyan, G. Daugaard, I. D. Davis, M. De Santis, C. G. Drake, R. A. Eeles, S. Fanti, M. E. Gleave, A. Heidenreich, M. Hussain, N. D. James, F. E. Lecouvet, C. J. Logothetis, K. Mastris, S. Nilsson, W. K. Oh, D. Olmos, A. R. Padhani, C. Parker, M. A. Rubin, J. A. Schalken, H. I. Scher, A. Sella, N. D. Shore, E. J. Small, C. N. Sternberg, H. Suzuki, C. J. Sweeney, I. F. Tannock & B. Tombal

Ann Oncol 2015; 26: 1589–1604 (doi: 10.1093/annonc/mdv257)

The funding note for this publication was incomplete; the full funding note should read as follows:

funding

We gratefully acknowledge the financial support of the following non-profit organisations for the Advanced Prostate Cancer Consensus Conference (APCCC): Cantonal Hospital St Gallen, City and Canton of St Gallen, Swiss Cancer Research Organisation, European School of Oncology (ESO), Swiss Cancer League, the Swiss Oncology Research Network SAKK,

Swiss Cancer Foundation, Prostate Cancer Foundation (PCF) and the Günter and Regine Kelm Foundation. We thank the Movember Foundation for the sponsoring of the travel grants (no grant number).

We also acknowledge sponsorship from several different for-profit organisations including Abbvie, Amgen, Astellas, AstraZeneca, Bayer Health Care, Bucherer, Dendreon, Janssen, Mundipharma, Myriad, Novartis, Roche, Sanofi Oncology, Teva. (Details on the www.apccc.org). These for-profit organisations supported the conference financially but had no input in the scientific content or the publication.